BioLargo Reports Q1 2025 Results: Assets Up, Net Loss Continues
Ticker: BLGO · Form: 10-Q · Filed: May 15, 2025 · CIK: 880242
Sentiment: bearish
Topics: 10-Q, financials, earnings-loss
TL;DR
BioLargo's Q1 2025: Assets nudged up to $301.7M, but still burning cash with a $5.3M net loss on $746k revenue.
AI Summary
BioLargo, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $301,760,373 as of March 31, 2025, a slight increase from $301,274,243 at the end of 2024. Revenue for the quarter was $746,418, with a net loss of $5,322,775.
Why It Matters
This filing provides insight into BioLargo's financial health and operational performance for the first quarter of 2025, crucial for investors assessing the company's trajectory.
Risk Assessment
Risk Level: medium — The company reported a significant net loss, indicating ongoing financial challenges that could impact its long-term viability.
Key Numbers
- $301.76M — Total Assets (As of March 31, 2025, showing a slight increase from year-end.)
- $746.42K — Revenue (Generated in the first quarter of 2025.)
- $5.32M — Net Loss (Incurred during the first quarter of 2025.)
- 0.00067 — Earnings Per Share (Diluted) (Reported for the quarter, indicating a loss.)
Key Players & Entities
- BIOLARGO, INC. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- $301,760,373 (dollar_amount) — Total assets as of March 31, 2025
- $301,274,243 (dollar_amount) — Total assets as of December 31, 2024
- $746,418 (dollar_amount) — Revenue for the quarter
- $5,322,775 (dollar_amount) — Net loss for the quarter
FAQ
What was BioLargo's total revenue for the quarter ending March 31, 2025?
BioLargo reported total revenue of $746,418 for the quarter ending March 31, 2025.
What was the company's net loss for the first quarter of 2025?
The company reported a net loss of $5,322,775 for the first quarter of 2025.
How did BioLargo's total assets change from December 31, 2024, to March 31, 2025?
Total assets increased slightly from $301,274,243 on December 31, 2024, to $301,760,373 on March 31, 2025.
What was the closing common stock price used for aggregate intrinsic value calculation as of March 31, 2025?
The aggregate intrinsic value was based on a closing common stock price of $0.28 at March 31, 2025.
What is BioLargo's fiscal year end?
BioLargo's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding BIOLARGO, INC. (BLGO).